Cargando…

Combination of IAP Antagonists and TNF-α-Armed Oncolytic Viruses Induce Tumor Vascular Shutdown and Tumor Regression

Smac mimetic compounds (SMCs) are anti-cancer drugs that antagonize Inhibitor of Apoptosis proteins, which consequently sensitize cancer cells to death in the presence of proinflammatory ligands such as tumor necrosis factor alpha (TNF-α). SMCs synergize with the attenuated oncolytic vesicular stoma...

Descripción completa

Detalles Bibliográficos
Autores principales:	Beug, Shawn T., Pichette, Stephanie J., St-Jean, Martine, Holbrook, Janelle, Walker, Danielle E., LaCasse, Eric C., Korneluk, Robert G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Gene & Cell Therapy 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6076221/ https://www.ncbi.nlm.nih.gov/pubmed/30101187 http://dx.doi.org/10.1016/j.omto.2018.06.002

Ejemplares similares

Sp3-cificity of TNF-α expression promotes the Smac mimetic-mediated killing of cancer cells
por: Beug, Shawn T., et al.
Publicado: (2019)

Targeted ablation of the cellular inhibitor of apoptosis 1 (cIAP1) attenuates denervation-induced skeletal muscle atrophy
por: Lala-Tabbert, Neena, et al.
Publicado: (2019)

Smac mimetics combined with innate immune stimuli create the perfect cytokine storm to kill tumor cells
por: Beug, Shawn T, et al.
Publicado: (2014)

Oncolytic virus synergizes with Smac mimetic compounds to induce rhabdomyosarcoma cell death in a syngeneic murine model
por: Dobson, Christine C, et al.
Publicado: (2016)

Inhibitor of apoptosis proteins, NAIP, cIAP1 and cIAP2 expression during macrophage differentiation and M1/M2 polarization
por: Morón-Calvente, Virginia, et al.
Publicado: (2018)

Taking aim with IAP antagonists at triple-negative breast cancer: a moving target no more?
por: LaCasse, Eric C.
Publicado: (2020)

Smac mimetics and innate immune stimuli synergize to promote tumor death
por: Beug, Shawn T., et al.
Publicado: (2014)

Role of the TWEAK-Fn14-cIAP1-NF-κB Signaling Axis in the Regulation of Myogenesis and Muscle Homeostasis
por: Enwere, Emeka K., et al.
Publicado: (2014)

LCL161 enhances expansion and survival of engineered anti-tumor T cells but is restricted by death signaling
por: Afsahi, Arya, et al.
Publicado: (2023)

Bivalent IAP antagonists, but not monovalent IAP antagonists, inhibit TNF-mediated NF-κB signaling by degrading TRAF2-associated cIAP1 in cancer cells
por: Mitsuuchi, Y, et al.
Publicado: (2017)

IAP antagonists sensitize murine osteosarcoma cells to killing by TNFα
por: Shekhar, Tanmay M., et al.
Publicado: (2016)

Bivalent IAP antagonists inhibit TRAF2-bound cIAPs and limit TNF-mediated NF-κB signaling
por: Condon, Stephen M
Publicado: (2016)

SMG1 and NIK regulate apoptosis induced by Smac mimetic compounds
por: Cheung, H H, et al.
Publicado: (2011)

Publisher Correction: Smac mimetics synergize with immune checkpoint inhibitors to promote tumour immunity against glioblastoma
por: Beug, Shawn T., et al.
Publicado: (2018)

Smac mimetics synergize with immune checkpoint inhibitors to promote tumour immunity against glioblastoma
por: Beug, Shawn T., et al.
Publicado: (2017)

IAP antagonist GDC-0917 is more potent than Debio1143 in promoting cell death, c-IAP1 degradation and tumor growth inhibition
por: Alicke, Bruno, et al.
Publicado: (2022)

Armed oncolytic viruses: A kick-start for anti-tumor immunity
por: de Graaf, J.F., et al.
Publicado: (2018)

Triggering necroptosis in cisplatin and IAP antagonist-resistant ovarian carcinoma
por: McCabe, K E, et al.
Publicado: (2014)

Lipopolysaccharide sensitizes the therapeutic response of breast cancer to IAP antagonist
por: Liu, Xin, et al.
Publicado: (2022)

The expanding role of IAP antagonists for the treatment of head and neck cancer
por: Kansal, Vikash, et al.
Publicado: (2023)

5th IAP Astrophysics Meeting
por: Audouze, Jean, et al.
Publicado: (1990)

Abscopal Effect in Non-injected Tumors Achieved with Cytokine-Armed Oncolytic Adenovirus
por: Havunen, Riikka, et al.
Publicado: (2018)

2nd IAP Astrophysics Meeting
por: Audouze, Jean, et al.
Publicado: (1986)

Exploratory window‐of‐opportunity trial to investigate the tumor pharmacokinetics/pharmacodynamics of the IAP antagonist Debio 1143 in patients with head and neck cancer
por: Gomez‐Roca, Carlos, et al.
Publicado: (2021)

Drosophila IAP antagonists form multimeric complexes to promote cell death
por: Sandu, Cristinel, et al.
Publicado: (2010)

Clinical Positioning of the IAP Antagonist Tolinapant (ASTX660) in Colorectal Cancer
por: Crawford, Nyree, et al.
Publicado: (2021)

Beyond cancer cells: Targeting the tumor microenvironment with gene therapy and armed oncolytic virus
por: Wan, Peter Kok-Ting, et al.
Publicado: (2021)

IAP inhibitors enhance co-stimulation to promote tumor immunity
por: Dougan, Michael, et al.
Publicado: (2010)

The IAP antagonist birinapant potentiates bortezomib anti-myeloma activity in vitro and in vivo
por: Zhou, Liang, et al.
Publicado: (2019)

Role of A20 in cIAP-2 Protection against Tumor Necrosis Factor α (TNF-α)-Mediated Apoptosis in Endothelial Cells
por: Guo, Shuzhen, et al.
Publicado: (2014)

Activation of noncanonical NF-κB requires coordinated assembly of a regulatory complex of the adaptors cIAP1, cIAP2, TRAF2, TRAF3 and the kinase NIK
por: Zarnegar, Brian J., et al.
Publicado: (2008)

[Shutdown]
por: CERN Press Office. Geneva
Publicado: (1980)

Ceramide targets xIAP and cIAP1 to sensitize metastatic colon and breast cancer cells to apoptosis induction to suppress tumor progression
por: Paschall, Amy V, et al.
Publicado: (2014)

IAP Workshop
Publicado: (1996)

TWEAK-FN14 signaling induces lysosomal degradation of a cIAP1–TRAF2 complex to sensitize tumor cells to TNFα
por: Vince, James E., et al.
Publicado: (2008)

Human Retrotransposons and the Global Shutdown of Homeostatic Innate Immunity by Oncolytic Parvovirus H-1PV in Pancreatic Cancer
por: Neulinger-Muñoz, Matthias, et al.
Publicado: (2021)

Tumor Restrictions to Oncolytic Virus
por: Vähä-Koskela, Markus, et al.
Publicado: (2014)

Oncolytic Virotherapy in Glioma Tumors
por: Rius-Rocabert, Sergio, et al.
Publicado: (2020)

Oncolytic virotherapy with an armed vaccinia virus in an orthotopic model of renal carcinoma is associated with modification of the tumor microenvironment
por: Fend, Laetitia, et al.
Publicado: (2015)

IL-21 arming potentiates the anti-tumor activity of an oncolytic vaccinia virus in monotherapy and combination therapy
por: Chen, Tianyue, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_tg3adaggs0l3el3ht4ro2ib118